{"symbol":"ABBV","fiscalQuarter":"Q2-2026","reportDate":"2026-07-30","reportTime":"BMO","status":"upcoming","company":{"name":"AbbVie Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/ABBV/earnings/Q2-2026","estimates":{"consensusEps":3.6084,"consensusRevenue":16755.56,"epsLow":3.54,"epsHigh":3.71,"whisperEps":null,"numAnalysts":null},"preBrief":{"companySnapshot":"AbbVie Inc. is a global biopharmaceutical company focused on developing advanced therapies for complex diseases. With a market cap of $443 billion, it plays a significant role in the healthcare sector, particularly in immunology, oncology, and neuroscience.","keyMetrics":[{"name":"EPS","why":"Earnings per share is a key indicator of profitability and helps gauge the company's financial health.","consensus":"$3.61"},{"name":"Revenue","why":"Total revenue shows the company's ability to generate sales and is crucial for assessing growth.","consensus":"$16.8B"}],"lastQuarterRecap":{"summary":"In Q1-2026, AbbVie reported an EPS of $2.65, slightly beating estimates. However, revenue details were not disclosed, leading to a 3.14% increase in stock price the following day.","promises":[]},"wallStreetExpectations":{"summary":"Analysts expect AbbVie to report strong earnings this quarter, with a consensus EPS of $3.61. The market is closely watching revenue figures to assess growth prospects.","bullCase":"If AbbVie exceeds EPS and revenue expectations, it could signal strong demand for its products and boost investor confidence.","bearCase":"Conversely, if the company misses estimates or provides weak guidance, it may raise concerns about its growth trajectory and lead to a decline in stock price."},"optionsSignal":{"impliedMove":"5.85%","context":"The options market is pricing in a significant move around the earnings report, indicating heightened investor uncertainty."},"earningsTrackRecord":[{"quarter":"Q1-2026","epsSurprise":"+1.30%","reaction":"+3.14%"},{"quarter":"Q4-2025","epsSurprise":"+2.03%","reaction":"-3.79%"},{"quarter":"Q3-2025","epsSurprise":"+4.91%","reaction":"-4.45%"},{"quarter":"Q2-2025","epsSurprise":"-8.39%","reaction":"-0.15%"},{"quarter":"Q1-2025","epsSurprise":"+2.93%","reaction":"+3.15%"},{"quarter":"Q4-2024","epsSurprise":"+1.27%","reaction":"+4.70%"},{"quarter":"Q3-2024","epsSurprise":"+2.67%","reaction":"+6.36%"},{"quarter":"Q2-2024","epsSurprise":"+3.03%","reaction":"+3.38%"}],"pivotalQuestions":[{"question":"Will AbbVie achieve an EPS of $3.61 or higher?","whyItMatters":"This figure is crucial for assessing the company's profitability and could significantly impact investor sentiment."},{"question":"What will the revenue figure be, and how does it compare to the consensus of $16.8B?","whyItMatters":"Revenue growth is essential for evaluating the company's market position and future prospects."}],"thesisBreakLevels":{"bullTrigger":"Reporting an EPS of $3.71 or higher with revenue exceeding $17.0B would confirm the bull case.","bearTrigger":"An EPS below $3.54 or revenue below $16.5B would support the bear case.","context":"The market is focused on both earnings and revenue growth to gauge AbbVie's performance and future potential."},"scenarioPlaybook":{"beatAndRaise":"If AbbVie beats expectations, history suggests a potential stock increase of around 1.78%, confirming strong demand for its products.","inLineCautious":"If results are in line with expectations, the stock may see muted movement as investors await further guidance.","miss":"A miss could lead to a decline, with historical data suggesting an average drop of 0.15% following such outcomes."},"peerReadThroughs":[],"setupPatternInsight":{"pattern":"Prior-quarter beat + options rich in Health Care","sampleSize":30,"fadeRate":"13 of 29 (45%)","insight":"This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held \u2014 no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias)."},"whatTheStreetIsMissing":{"thesis":"The consensus may underestimate AbbVie's potential for revenue growth given recent product launches and market demand.","supportingPoints":["AbbVie has a history of beating EPS estimates, suggesting strong operational performance.","The options market indicates a significant expected move, reflecting uncertainty that could be resolved positively.","Recent trends in the biotech sector show increased demand for innovative therapies, which AbbVie is well-positioned to capitalize on."],"riskToConsensus":"If revenue comes in below $16.5B, it could challenge the bullish outlook."},"whatToListenFor":["Any updates on new product launches and their expected impact on revenue.","Insights into market demand for AbbVie's key therapies.","Management's outlook on competitive pressures in the biotechnology sector.","Details on cost management strategies and their effect on profitability.","Any commentary on regulatory developments that could impact future sales."],"metaDescription":"AbbVie (ABBV) reports Q2 2026 earnings July 30. Analysts expect $3.61 EPS on $16.8B revenue. Here's what to watch."}}